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background: Several antithrombotic medications used during percutaneous coronary intervention (PCI) are contraindicated for specific 
patient groups. Little is known about the use and clinical implications of contraindicated medication use in PCI.
Methods:  Using national VA CART Program data for all PCI from 2007-2013, we evaluated patient subgroups with contraindications to 
commonly used antithrombotics (Table). After identifying antithrombotics most frequently used in contraindicated settings, we determined 
the risk-adjusted association between contraindicated use of these medications and outcomes of bleeding and mortality from Cox 
proportional hazards models among cohorts with similar contraindications.
results:  Among 12,090 patients with a contraindication to common antithrombotic medications, 845 (7%) received a contraindicated 
medication. Abxicimab and eptifibitide were most frequently used in contraindicated settings (Table). In unadjusted and risk-adjusted 
analyses, contraindicated abciximab use was associated with increased bleeding in patients with thrombocytopenia or prior stroke and 
increased mortality in patients with thrombocytopenia (Table).
conclusion:  In patients with contraindications to common antithrombotic medications used during PCI, nearly 1 in 10 received a 
contraindicated medication with attendent bleeding and mortality risk. Strategies to avoid use of contraindicated medications are needed to 
minimize these avoidable PCI complications.
